Skip to main content
SpringerLink
Log in

Anticoagulation in Venous Thromboembolism

  • Chapter
  • First Online:
Anticoagulation Therapy

  • 2094 Accesses

Abstract

Venous thromboembolism (VTE) is a highly prevalent and potentially dangerous condition. While anticoagulation is the mainstay of therapy, thrombolytic therapy may be utilized in the acute setting for select patients. In this chapter, we review the risk factors for development of VTE and the key decision-making considerations for treatment. We highlight the role of acute therapies, such as thrombolytics, as well as appropriate selection of oral anticoagulants. Key advantages and disadvantages of warfarin and the direct oral anticoagulants are summarized. We review key aspects for chronic anticoagulation management, including the use of formal anticoagulation clinics. Finally, we discuss approaches to VTE recurrence risk stratification and the selection of antithrombotic agents for secondary VTE prevention. Numerous tables and figures outline decision-making steps and provide summary data from pivotal randomized trials in VTE management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Goldhaber SZ. Risk factors for venous thromboembolism. J Am Coll Cardiol. 2010;56(1):1–7.

    Article  PubMed  Google Scholar 

  2. The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. Rockville (MD). 2008. https://www.ncbi.nlm.nih.gov/pubmed/20669525.

  3. Writing Group M, Mozaffarian D, Benjamin EJ, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38–360.

    Article  Google Scholar 

  4. Spyropoulos AC, Hurley JS, Ciesla GN, de Lissovoy G. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. Chest. 2002;122(1):108–14.

    Article  PubMed  Google Scholar 

  5. De Martino RR, Wallaert JB, Rossi AP, Zbehlik AJ, Suckow B, Walsh DB. A meta-analysis of anticoagulation for calf deep venous thrombosis. J Vasc Surg. 2012;56(1):228–37. e221; discussion 236-227.

    Article  PubMed  Google Scholar 

  6. Palareti G. How I treat isolated distal deep vein thrombosis (IDDVT). Blood. 2014;123(12):1802–9.

    Article  CAS  PubMed  Google Scholar 

  7. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S–94S.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Brandjes DP, Heijboer H, Buller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1992;327(21):1485–9.

    Article  CAS  PubMed  Google Scholar 

  9. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–52.

    Article  CAS  PubMed  Google Scholar 

  10. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–510.

    Article  CAS  PubMed  Google Scholar 

  11. Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–97.

    Article  PubMed  Google Scholar 

  12. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808.

    Article  CAS  PubMed  Google Scholar 

  13. Hokusai VTEI, Buller HR, Decousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406–15.

    Article  Google Scholar 

  14. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–52.

    Article  PubMed  Google Scholar 

  15. Streiff MB, Agnelli G, Connors JM, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis. 2016;41(1):32–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Barnes GD, Kanthi Y, Froehlich JB. Venous thromboembolism: predicting recurrence and the need for extended anticoagulation. Vasc Med. 2015;20(2):143–52.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(43):3033–69, 3069a-3069k.

    Article  CAS  PubMed  Google Scholar 

  18. Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123(16):1788–830.

    Article  PubMed  Google Scholar 

  19. Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370(15):1402–11.

    Article  CAS  PubMed  Google Scholar 

  20. Bartel B. Systemic thrombolysis for acute pulmonary embolism. Hosp Pract. 2015;43(1):22–7.

    Article  Google Scholar 

  21. Wang C, Zhai Z, Yang Y, et al. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest. 2010;137(2):254–62.

    Article  CAS  PubMed  Google Scholar 

  22. Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M, Investigators M. Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” trial). Am J Cardiol. 2013;111(2):273–7.

    Article  PubMed  Google Scholar 

  23. Kucher N, Boekstegers P, Muller OJ, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation. 2014;129(4):479–86.

    Article  PubMed  Google Scholar 

  24. Kahn SR, Comerota AJ, Cushman M, et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2014;130(18):1636–61.

    Article  PubMed  Google Scholar 

  25. Enden T, Haig Y, Klow NE, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet. 2012;379(9810):31–8.

    Article  PubMed  Google Scholar 

  26. Stein PD, Matta F, Keyes DC, Willyerd GL. Impact of vena cava filters on in-hospital case fatality rate from pulmonary embolism. Am J Med. 2012;125(5):478–84.

    Article  PubMed  Google Scholar 

  27. Stein PD, Matta F, Sabra MJ. Case fatality rate with vena cava filters in hospitalized stable patients with cancer and pulmonary embolism. Am J Med. 2013;126(9):819–24.

    Article  PubMed  Google Scholar 

  28. Stein PD, Matta F. Vena cava filters in unstable elderly patients with acute pulmonary embolism. Am J Med. 2014;127(3):222–5.

    Article  PubMed  Google Scholar 

  29. Group PS. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (prevention du Risque d’Embolie Pulmonaire par interruption cave) randomized study. Circulation. 2005;112(3):416–22.

    Article  Google Scholar 

  30. Mismetti P, Laporte S, Pellerin O, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial. JAMA. 2015;313(16):1627–35.

    Article  PubMed  Google Scholar 

  31. Weinberg I, Abtahian F, Debiasi R, et al. Effect of delayed inferior vena cava filter retrieval after early initiation of anticoagulation. Am J Cardiol. 2014;113(2):389–94.

    Article  PubMed  Google Scholar 

  32. Kinney TB, Aryafar H, Ray Jr CE, et al. ACR Appropriateness Criteria radiologic management of inferior vena cava filters. Expert panel on interventional radiology. 2012. https://guidelines.gov/summaries/summary/43868. Accessed 1 Dec 2016.

  33. Caplin DM, Nikolic B, Kalva SP, et al. Quality improvement guidelines for the performance of inferior vena cava filter placement for the prevention of pulmonary embolism. J Vasc Interv Radiol. 2011;22(11):1499–506.

    PubMed  Google Scholar 

  34. Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764–72.

    Article  CAS  PubMed  Google Scholar 

  35. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304–14.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484–8.

    Article  CAS  PubMed  Google Scholar 

  37. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146–53.

    Article  CAS  PubMed  Google Scholar 

  38. Lee AY, Kamphuisen PW, Meyer G, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314(7):677–86.

    Article  CAS  PubMed  Google Scholar 

  39. Posch F, Konigsbrugge O, Zielinski C, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res. 2015;136(3):582–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125(1):1–7.

    Article  CAS  PubMed  Google Scholar 

  41. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362(9383):523–6.

    Article  PubMed  Google Scholar 

  42. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med. 2004;350(25):2558–63.

    Article  CAS  PubMed  Google Scholar 

  43. Kovacs MJ, Kahn SR, Wells PS, et al. Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism. J Thromb Haemost. 2010;8(9):1926–32.

    Article  CAS  PubMed  Google Scholar 

  44. Streiff MB. Predicting the risk of recurrent venous thromboembolism (VTE). J Thromb Thrombolysis. 2015;39(3):353–66.

    Article  CAS  PubMed  Google Scholar 

  45. Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008;179(5):417–26.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121(14):1630–6.

    Article  PubMed  Google Scholar 

  47. Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost. 2012;10(6):1019–25.

    Article  CAS  PubMed  Google Scholar 

  48. Rodger MA, Scarvelis D, Kahn SR, et al. Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: a multi-national cohort. Thromb Res. 2016;143:152–8.

    Article  CAS  PubMed  Google Scholar 

  49. Marcucci M, Iorio A, Douketis JD, et al. Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna prediction model with pooled individual patient data. J Thromb Haemost. 2015;13:775–81.

    Article  CAS  PubMed  Google Scholar 

  50. Ruiz-Gimenez N, Suarez C, Gonzalez R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE registry. Thromb Haemost. 2008;100(1):26–31.

    Article  CAS  PubMed  Google Scholar 

  51. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349(7):631–9.

    Article  CAS  PubMed  Google Scholar 

  52. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348(15):1425–34.

    Article  CAS  PubMed  Google Scholar 

  53. Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709–18.

    Article  CAS  PubMed  Google Scholar 

  54. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699–708.

    Article  CAS  PubMed  Google Scholar 

  55. Weitz JI, Lensing WA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376:1211–22.

    Article  CAS  PubMed  Google Scholar 

  56. Carrier M, Rodger MA, Wells PS, Righini M, LEG G. Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost. 2011;9(6):1119–25.

    Article  CAS  PubMed  Google Scholar 

  57. Cosmi B, Legnani C, Cini M, Guazzaloca G, Palareti G. D-dimer and residual vein obstruction as risk factors for recurrence during and after anticoagulation withdrawal in patients with a first episode of provoked deep-vein thrombosis. Thromb Haemost. 2011;105(5):837–45.

    Article  CAS  PubMed  Google Scholar 

  58. Kearon C, Spencer FA, O’Keeffe D, et al. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med. 2015;162(1):27–34.

    Article  PubMed  Google Scholar 

  59. Timp JF, Lijfering WM, Flinterman LE, et al. Predictive value of factor VIII levels for recurrent venous thrombosis: results from the MEGA follow-up study. J Thromb Haemost. 2015;13(10):1823–32.

    Article  CAS  PubMed  Google Scholar 

  60. Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366(21):1959–67.

    Article  CAS  PubMed  Google Scholar 

  61. Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367(21):1979–87.

    Article  CAS  PubMed  Google Scholar 

  62. Chopra V, Anand S, Hickner A, et al. Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis. Lancet. 2013;382(9889):311–25.

    Article  PubMed  Google Scholar 

  63. Chopra V, Ratz D, Kuhn L, Lopus T, Lee A, Krein S. Peripherally inserted central catheter-related deep vein thrombosis: contemporary patterns and predictors. J Thromb Haemost. 2014;12(6):847–54.

    Article  CAS  PubMed  Google Scholar 

  64. Chopra V, Flanders SA, Saint S, et al. The Michigan appropriateness guide for intravenous catheters (MAGIC): results from a multispecialty panel using the RAND/UCLA appropriateness method. Ann Intern Med. 2015;163(6 Suppl):S1–40.

    Article  PubMed  Google Scholar 

  65. Ageno W, Beyer-Westendorf J, Garcia DA, Lazo-Langner A, McBane RD, Paciaroni M. Guidance for the management of venous thrombosis in unusual sites. J Thromb Thrombolysis. 2016;41(1):129–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Dentali F, Gianni M, Crowther MA, Ageno W. Natural history of cerebral vein thrombosis: a systematic review. Blood. 2006;108(4):1129–34.

    Article  CAS  PubMed  Google Scholar 

  67. Ageno W, Riva N, Schulman S, et al. Long-term clinical outcomes of splanchnic vein thrombosis: results of an international registry. JAMA Intern Med. 2015;175(9):1474–80.

    Article  PubMed  Google Scholar 

  68. Group CVOS. Natural history and clinical management of central retinal vein occlusion. The central vein occlusion study group. Arch Ophthalmol. 1997;115(4):486–91.

    Article  Google Scholar 

  69. Decousus H, Quere I, Presles E, et al. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med. 2010;152(4):218–24.

    Article  PubMed  Google Scholar 

  70. Decousus H, Prandoni P, Mismetti P, et al. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med. 2010;363(13):1222–32.

    Article  CAS  PubMed  Google Scholar 

  71. Amin AN, Varker H, Princic N, Lin J, Thompson S, Johnston S. Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. J Hosp Med. 2012;7:231–8.

    Article  PubMed  Google Scholar 

  72. Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, et al. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016;375:534–44.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Cardiovascular Medicine, Frankel Cardiovascular Center at the University of Michigan, Ann Arbor, MI, USA

    Geoffrey D. Barnes

  2. Anticoagulation Service, Faculty Group Practice: Pharmacy Innovations and Partnerships, University of Michigan, Ann Arbor, MI, USA

    Elizabeth T. Renner

Authors
  1. Geoffrey D. Barnes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth T. Renner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Geoffrey D. Barnes .

Editor information

Editors and Affiliations

  1. Associate Professor of Cardiology, Department of Cardiology, Zucker School of Medicine at Hofstra/Northwell, Northwell Health, Manhasset, New York, USA

    Joe F. Lau

  2. Assistant Professor, Division of Internal Medicine, Frankel Cardiovascular Center at the University of Michigan, Ann Arbor, Michigan, USA

    Geoffrey D. Barnes

  3. Professor of Medicine and Pathology, Division of Hematology, Department of Medicine, The Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA

    Michael B. Streiff

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Barnes, G.D., Renner, E.T. (2018). Anticoagulation in Venous Thromboembolism. In: Lau, J., Barnes, G., Streiff, M. (eds) Anticoagulation Therapy . Springer, Cham. https://doi.org/10.1007/978-3-319-73709-6_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-73709-6_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-73708-9

  • Online ISBN: 978-3-319-73709-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation